

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: **14-12-2006**

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEK-ENDING 12-8-2006 TO BE PUBLISHED ON 14-12-2006
IN THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

| | | |
|----------|---|---|
| 932/2006 | <u>07-8-2006</u> ENI S.P.A. and Polimeri Europa S.p.A., Italy (Priority 10-8-05 Italy) | “Process for the removal of filtercakes in oil wells” |
| 933/2006 | <u>08-8-2006</u> The university of Queensland, Australia | “ Method for improving plants to achieves” |
| 934/2006 | The university of Queensland, Australia | “ A Method for producing isomaltulose” |
| 935/2006 | The university of Queensland, Australia | “ A Method for production of higher yields of a desired metabolite ” |
| 936/2006 | The university of Queensland, Australia | “ A process for producing soluble carbohydrates” |
| 937/2006 | 1. Saudi Basic Industries Corporation Saudi Arabia 2. Linde Ag., Germany (Priority 10-8-05 Europe) | “ Improved method for preparation of linear alpha-olefins and reactor system therefore” |
| 938/2006 | 1. Saudi Basic Industries Corporation Saudi Arabia 2. Linde Ag., Germany (Priority 10-8-05 Europe) | “ Method for deactivation and removal of catalytic components in the oligomerisation of ethylene” |
| 939/2006 | SmithKline Beecham Corporation, USA (Priority 10-8-05 GB) | “ Novel Compounds” |
| 940/2006 | Glaxo Group Limited, Great Britain (Priority 9-8-05 GB) | “ Compounds” |

| | | |
|----------|--|--|
| 941/2006 | <u>09-8-2006</u> Novartis AG., Switzerland (Priority 09-8-05 USA) | “ Substituted imidazole compounds as KSP inhibitors” |
| 942/2006 | 1. Farzana Azmat 2. Dr. Kaneez Fatima Ahmad 3. Mahmood-ul-Hassan and 4. Dr. Nighat Afza PCSIR, Karachi Pakistan. | “ A process for the production of insect repellent oil “Mos-Shoo” |
| 943/2006 | 1. Farzana Azmat 2. Dr. Kaneez Fatima Ahmad 3. Mahmood-ul-Hassan and 4. Dr. Nighat Afza PCSIR, Karachi Pakistan. | “ A process for the production of insect repellent oil “Mos-Shoo” |
| 944/2006 | Bajaj Auto Limited, India (Priority 09-8-05 India) | “ Vehicle frame and method of manufacturing a vehicle” |
| 945/2006 | Novartis AG., Switzerland (Priority 09-8-05 USA) | “ Liquid formulations” |
| 946/2006 | BASF Aktiengesellschaft, Germany (Priority 11-8-05 USA) | “ Pesticidal mixtures” |
| 947/2006 | Novartis AG., Switzerland (Priority 10-8-05 USA) | “ Organic compounds” |
| 948/2006 | <u>10-8-2006</u> Boehringer Ingelheim International GmbH, Germany (Priority 12-8-05 Europe) | “ HFC solution formulations containing salbutamol hydrochloride or salbutamol citrate” |
| 949/2006 | Auburn University USA (Priority 11-8-05 USA) | “ N-halmine/quaternary ammoniumpolysiloxane” |
| 950/2006 | Bayer CropScience AG., Germany (Priority 09-9-05 Germany) | “ Use of CNI SL formulations for controlling whitefly” |

| | | |
|----------|--|---|
| 951/2006 | AstraZeneca AB, Sweden (Priority 12-8-05GB) | “ Amide derivative” |
| | <u>11-8-2006</u> | |
| 952/2006 | Borg Warner Inc., USA (Priority 15-8-05 USA) | “ Continuously variable transmission” |
| 953/2006 | 1.Tibotec Pharmaceuticals Ltd Ireland 2. Medivir AB., Sweden (Priority 8-11-05 Sweden) | “ HIV protease inhibitors” |
| 954/2006 | Molisa GmbH, Germany (Priority 24-8-05 Europe) | “ N-substituted 2-(6-oxo-6,7-dihydro-5H-benzo[2,3]azep ino[4,5-b] indol-5-yl)-acetamides for treating tropical diseases” |
| 955/2006 | Shell International Research Maatschappij B.V. The Netherlands (Priority 12-8-05 Europe) | “ Fuel Composition” |
| | <u>12-8-2006</u> | |
| 956/2006 | Novartis AG., Switzerland (Priority 15-8-05 GB) | “ Benzoquinazoline derivatives” |
| 957/2006 | Xstrata Technology Pty Ltd., Australia (Priority 15-8-05 Australia) | “ Method for increasing efficiency of grinding of ores, minerals and concentrates” |
| 958/2006 | Wyeth, USA (Priority 15-12-2001 USA) Divisional | “ Pharmaceutically acceptable salts of substituted benzoxazoles as estrogenic agents” |
| 959/2006 | Wyeth, USA (Priority 14-2-2003 USA) Divisional | “ Pharmaceutically acceptable salts of heterocycl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands” |
| 960/2006 | Wyeth, USA (Priority 04-6-2002 USA) Divisional | “ Pharmaceutically acceptable salts of 1-(aminoalkyl)-3-sulfonylazainodoles useful as 5-hydroxytryptamine-6 ligands” |

| | | |
|----------|--|---|
| 961/2006 | Wyeth, USA (Priority 17-10-2000 USA) Divisional | “ Salts of a compound comprising a pharmaceutical composition for use in maintaining the bladder control” |
| 962/2006 | Wyeth Holdings Corporation, USA (Priority 27-11-2001 USA) Divisional | “ Pharmaceutically acceptable salts of 3-cyanoquino-lines as inhibitors of EGF-R and HER2 kinases” |
| 963/2006 | Wyeth, USA (Priority 20-6-2001 USA) Divisional | “ Pharmaceutically acceptable salts and esters of substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1(PAI-1)” |
| 964/2006 | Wyeth, USA (Priority 24-11-99 USA) Divisional | “ Ethers of o-desmethyl venlafaxine in the form of pharmaceutically acceptable salts or hydrates” |
| 965/2006 | Boehringer Ingelheim International GmbH, Germany (Priority 15-8-05 Europe) | “ Process for the manufacturing of betamimetics” |
| 966/2006 | Wyeth, USA (Priority 15-8-2005 USA) | “ substituted-3- sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands” |
| 967/2006 | Wyeth, USA (Priority 15-8-2005 USA) | “ Azinyl-3-sulfonylindazole derivatives as 5-hydroxy tryptamine-6 ligands” |
| 968/2006 | Syngenta Participations AG., Switzerland (Priority 15-8-05 UK) | “ Novel Insecticides” |
| 969/2006 | DE LA Rue International Ltd United Kingdom (Priority 15-8-05 U.K) | “ Security devices for security substrates” |

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicated their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

896/2004

Wyeth,
USA

“A process for preparing a 3-hydroxy quinoline 4-carboxylic acid or analogue thereof for treating selectin mediated disorders”

(Class: INT.CL.7: C07D 221/02)

139200

Comprising to:
2-(4-chlorobenzyl)-3-hydroxy-8-trifluoromethyl-quinoline-4-carboxylic acid compound to its process of preparation to its pharmaceutical composition comprising it, useful for treating mammals selectin mediated disorders.

901/2004

Smithkline Beecham
Corporation,
USA

“A novel crystalline form of topotecan monohydrochloride pentahydrate for the treatment of anti-viral and/or cancer-related diseases”

(Class: C07D, 498/22)

139201

Comprises the steps of

- a) forming an aqueous organic solvent mixture containing topotecan monohydrochloride
- b) recrystallizing the topotecan monohydrochloride from and/or slurring the topotecan monohydrochloride with the aqueous organic solvent mixture to precipitate and/or for the topotecan monohydrochloride pentahydrate product and
- c) collecting by filtration, said compound.

| | | | |
|-----------|--|---|--------|
| 902/2004 | Freedom Health, LLC, USA | <p>“A dietary supplement comprising a polar lipid supplement, a soluble beta-glucan fiber and at least one amino acid for the treatment and prevention of digestive system and digestive system-related disorders”</p> <p>(Class: A61K, 38/02)</p> | 139202 |
| | | <p>Comprising providing a polar lipid supplement which contains significant amounts of polar lipid and antioxidants, providing soluble beta glucan fibre providing at least one amino acid, mixing said polar lipid supplement, said soluble beta-glucan fiber and said amino acid which is capable of exerting at least one beneficial effect on a stressed digestive system together.</p> | |
| 903/2004 | Almirall Prodesfarma, S.A., Spain | <p>“Pyridazin-3-(2H)-one compound and its use as a PDE4 inhibitor”</p> <p>(Class: C07D, 237/14)</p> | 139203 |
| | | <p>Comprises 4-[(3-chlorophenyl)amino]2-ethyl-5(1-hydroxyethyl)6-phenyl pyridazina 2-(2H) one, to its pharmaceutical composition containing it, to its use for the treatment of asthma, chronic obstructive pulmonary diseases.</p> | |
| 911//2004 | BP Corporation North America Inc., USA | <p>“A process for oxidation of aromatic hydrocarbon materials”</p> <p>(Class: INT.CL.7: C07B, 33/00)</p> | 139204 |
| | | <p>This invention relates generally to an improved oxidation process for the conversion of one or more aromatic hydrocarbon materials having oxidizable substituents to their corresponding acid derivatives, and relates more particularly to such a process involving staged oxidation and recycle of residual oxygen from a second oxidation stage to a first oxidation stage.</p> | |

914/2004 The University of
Queensland,
Australia

“ Method for improving plants to achieve higher yields of an endogenous carbohydrate or of total or soluble carbohydrates“

(Class: INT.CL.7: C12N, 15/11)

139205

A method of improving plants, comprising selecting from a plurality of transgenic plants which comprise in their nucleome a polynucleotide that is operably connected to a transcriptional control element and that encodes a sugar-metabolizing enzyme that catalyzes the conversion of an endogenous sugar of the plant to an alien sugar, a transgenic plant that produces the sugar-metabolizing enzyme at a level or functional activity so that the total or soluble carbohydrate content or sweetness or the content of an endogenous carbohydrate of the sink tissue of the transgenic plant is increased as compared to that of the corresponding sink tissue of the control plant.

916/2004 Solvay (Societe Anonyme),
Belgium

“Catalyst containing active elements including copper deposited on an alumina and gas phase method using such a catalyst”

(Class: INT.CL.7: B01J, 21/04)

139206

This application relates to catalyst containing active elements including copper deposited on alumina containing at least 0.03 of titanium, expressed in metal form, per kg of alumina and method involving a gas phase reaction catalysed by said catalyst.

933/2006 The University of
Queensland,
Australia

“Method for improving plants to achieve higher yields of an endogenous carbohydrate or of total or soluble carbohydrates”

(Class: INT.CL.7: C12N, 15/11)

A method for improving plant, the method comprising cultivating a transgenic plant in a growth medium that supports the cultivation, wherein the transgenic plant has sink tissue which has an increased total or soluble carbohydrate content or sweetness or an increased content of an endogenous carbohydrate as compared to a corresponding sink tissue of a control plant, the transgenic plant comprising cells which comprise in their nucleome a polynucleotide that encodes a sugar-metabolizing enzyme catalyzing the conversion of an endogenous sugar of the plant to an alien sugar, wherein the polynucleotide is operably connected to a transcriptional control element that is functional in the plant cells, and wherein the sugar-metabolizing enzyme is produced at a level or functional activity so that the total or soluble carbohydrate content or sweetness or the content of the endogenous carbohydrate of the sink tissue of the transgenic plant is increased as compared to that of the corresponding sink tissue of the control plant.

934/2006 The University of
Queensland,
Australia

“ A method for producing isomaltulose”

(Class: INT.CL.7: C12N, 15/11)

A method for the producing isomaltulose, the method comprising expressing in a plant that normally accumulates sucrose as a storage reserve, an introduced polynucleotide that encodes the sucrose isomerase UQ68J which is optionally modified to confer sucrose isomerase activity selectively in the sucrose storage compartment.

935/2006 The University of
Queensland,
Australia

“A method for the production of higher yields of a
desired metabolite”

(Class: INT.CL.7: C12N, 15/11)

139209

A method for the production of higher yields of a
desired metabolite, the method comprising the
expression within an organism of an introduced
polynucleotide which encodes an enzyme that
catalyzes the conversion of an endogenous substrate
compound that is normally sensed by the organism
into a product compound that is not perceived in an
equivalent manner within the organism, with the effect
that metabolic flows are altered, resulting in the
accumulation of higher yields of desired endogenous
compounds.

936/2006 The University of
Queensland,
Australia

“A process of producing soluble carbohydrates”

(Class: INT.CL.7: C12N, 15/11)

139210

A process of producing soluble carbohydrates, the
process comprising harvesting soluble carbohydrates
from a plant or a sink tissue of the transgenic plant,
wherein the transgenic plant has sink tissue which has
an increased total or soluble carbohydrate content or
sweetness or an increased content of an endogenous
carbohydrate as compared to a corresponding sink
tissue of a control plant, the transgenic plant
comprising cells which comprise in their nucleome a
polynucleotide that encodes a sugar-metabolizing
enzyme catalyzing the conversion of an endogenous
sugar of the plant to an alien sugar, wherein the
polynucleotide is operably connected to a
transcriptional control element that is functional in the
plant cells, and wherein the sugar-metabolizing
enzyme is produced at a level or functional activity so
that the total or soluble carbohydrate content or
sweetness or the content of the endogenous

carbohydrate of the sink tissue of the transgenic plant is increased as compared to that of the corresponding sink tissue of the control plant.

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

| | | |
|--------|--|----------|
| 139014 | Boehringer INgelheim Microparts GmbH, Germany | 531/2004 |
| 139015 | Novartis AG, Switzerland | 532/2004 |
| 139016 | Bayer Pharmaceuticals Corporation, USA | 533/2004 |
| 139017 | The Quarke Oats Company, USA | 606/2004 |
| 139018 | F.L. Smmidth A/S, Denmark | 647/2004 |
| 139019 | Tokue Inc., Japan | 805/2004 |

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Tel: 9215488